All In MedTech

FDA Clearance Tracker · P100020-S008

COBAS HPV TEST

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Apr 24, 2014 (this decision)Source: openFDAMethods & limitations

PMA supplement

The decision

FDA number
P100020-S008
Device name
COBAS HPV TEST
Applicant location
Pleasanton, CA
Received
Jul 1, 2013
Decided
Apr 24, 2014
Decision
Approved
Supplement type
Panel Track
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P100020

Device type

Device class
Class III

Every decision under product code MAQ

FDA's approval statement

As written in FDA's record.

APPROVAL FOR THE COBAS® HPV TEST. THE COBAS® HPV TEST INDICATIONS FOR USE: THE COBAS® HPV TEST IS A QUALITATIVE IN VITRO TEST FOR THE DETECTION OF HUMAN PAPILLOMAVIRUS IN CERVICAL SPECIMENS COLLECTED BY A CLINICIAN USING AN ENDOCERVICAL BRUSH/SPATULA AND PLACED IN THE THINPREP® PAP TESTTM PRESERVCYT® SOLUTION. THE TEST UTILIZES AMPLIFICATION OF TARGET DNA BY THE POLYMERASE CHAIN REACTION (PCR) AND NUCLEIC ACID HYBRIDIZATION FOR THE DETECTION OF 14 HIGH-RISK (HR) HPV TYPES IN A SINGLE ANALYSIS. THE TEST SPECIFICALLY IDENTIFIES TYPES HPV16 AND HPV18 WHILE CONCURRENTLY DETECTING THE REST OF THE HIGH RISK TYPES (31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 AND 68).THE COBAS® HHPV TEST IS INDICATED:1) TO SCREEN PATIENTS 21 YEARS AND OLDER WITH ASC-US (ATYPICAL SQUAMOUS CELLS OF UNDETERMINED SIGNIFICANCE) CERVICAL CYTOLOGY TEST RESULTS TO DETERMINE THE NEED FOR REFERRAL TO COLPOSCOPY; 2) TO BE USED IN PATIENTS PLEASE SEE APPROVAL ORDER FOR FURTHER INFORMATION.

Source documents

Other decisions for Roche Molecular Systems, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.